Common stock, par value $0.001 per share
- Symbol
- ANAB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 9.01 · 8-K
AnaptysBio, Inc.
ANABNASDAQEQUITYCurrent
Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Title or Description 99.1 Press release issued by AnaptysBio, Inc. regarding its financial results for the three months and transitional fiscal year ended June 30, 2026, dated September 21, 2026.…
Company context
Anaptys manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www. AnaptysBio.com or follow us on LinkedIn.
Current securities
Registered securities in this filing
ANAPTYSBIO, INC. · 8-K · Filed 2026-09-21
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number Exhibit Title or Description
99.1 Press release issued by AnaptysBio, Inc. regarding its financial results for the three months and transitional fiscal year ended June 30, 2026, dated September 21, 2026.
─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).
Filed exhibits (1)
Exhibit 99.1 Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update • Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth • Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decision • Litigation with GSK and Tesaro: trial held in July; post-trial hearing scheduled for October 20, 2026, with a judgement anticipated in Q4 2026 or Q1 2027 SAN DIEGO, Sept. 21, 2026 - AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update. “Jemperli continues to demonstrate robust year-over-year growth with major catalysts within the next 6 months…
Open exhibit ↗